GliaCure

About GliaCure

GliaCure is a biopharmaceutical company that specializes in the development of drugs for neuro-oncology. The company's primary focus is on addressing glial diseases, with a particular emphasis on glioblastoma, a type of brain tumor.

The company's lead asset, GC01, is a drug candidate that targets multiple indications within the neuro-oncology space. GliaCure's business model revolves around advancing its drug candidates through the clinical trial process. The company has a Scientific and Medical Advisory Board composed of experts in the field to guide its research and development efforts.

GliaCure's approach is centered on targeting glial cells, which are involved in various neurological and neuropsychiatric disorders. In addition to its work in neuro-oncology, the company has also been involved in research for Alzheimer's disease, with a compound that has undergone a Phase 1b study. The company's funding and development activities are supported by various partners and grants.